The National Institute of Pharmaceutical R&D (Beijing) has described bridged heterocyclyl-substituted pyrimidine compounds acting as tyrosine-protein kinase JAK-1 and/or non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of inflammation, autoimmune disease and cancer.